Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT02124577Unknown

Development of Kinetic Biomarkers of Liver Fibrosis Measuring NAFLD

Role: collaborator

NCT02438917Terminated

Biomarkers of Liver Fibrosis

Role: collaborator

NCT00476710Completed

Effects of Colesevelam HCl On Bile Acid Kinetics

Role: lead

NCT01348061Completed

Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls

Role: lead

NCT01092663Not ApplicableCompleted

The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus

Role: lead

NCT00765284Completed

Effect of Niaspan on Cholesterol in Men

Role: lead

NCT00481858Completed

Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis

Role: lead

All 7 trials loaded